.webp)
When You Can't Raise · Part 1 of 3
When You Can't Raise
- How AgTech Startups Grow When Venture Funding Dries Up (current)
- What Non-Dilutive Funding Is Available to AgTech Startups?
- When Should a Startup Cut Costs Instead of Chasing Revenue?
When venture funding is unavailable, ag and food tech startups have three real options: reach repeatable revenue, replace equity with non-dilutive capital, or preserve runway until the market reopens. PitchBook counted 263 agtech deals worth $2.4 billion in the first half of 2026, an annualized pace roughly 40% below last year, and does not expect a clear rebound until 2027. What makes this cycle different from previous agtech pullbacks is that the demand side tightened at the same time: USDA forecasts farm sector working capital down 9.2% in 2026 against record farm debt, so the customer expected to fund the revenue path has less to spend than last season. Most companies will use some combination of the three options. Only one can be the organizing priority, and refusing to choose is what turns a difficult year into a terminal one.
How bad is agtech venture funding in 2026?
Venture capitalists backed 263 agtech deals worth $2.4 billion in the first half of 2026, including just 107 in the second quarter, the lowest quarterly deal count in PitchBook's visible series. Against 875 deals in all of 2025, that is an annualized pace roughly 40% lower.
Treat the precision loosely and the direction seriously. Early counts in private market data revise upward as late deals get reported, so the final decline will likely be smaller than 40%. It will not be small.
What remains is concentrated. All ten of the largest H1 rounds went to late-stage companies, led by Tomorrow.io at $210 million and Oishii at $151.6 million. Exits stayed thin at 30 deals worth $623.2 million, and PitchBook does not expect a clear rebound until 2027, calling 2026 "the bottom of the cycle rather than the year of recovery."
The money did not disappear. It stopped arriving on the schedule most business plans assumed.
The funding market is also only half of the problem.
Why is this downturn different from the last one?
Because your customers are short of cash at the same time your investors are, and that has not been true in previous agtech pullbacks.
USDA forecasts farm sector working capital down 9.2% in 2026, against record farm debt of $624.7 billion and record interest expense of $33 billion. The Federal Reserve's July Beige Book put it in one sentence: "Agricultural conditions deteriorated due to lower commodity prices, higher input costs, and tighter credit." The Kansas City Fed found production loans declining at some of the largest agricultural lenders. Farmer sentiment fell to 113 on the Purdue/CME Ag Economy Barometer in June, but sentiment is the symptom. The balance sheet is the constraint.
That changes what the downturn is. In a capital-only downturn, the fix is to sell your way through it, and companies that got commercial discipline right came out ahead. That advice is still correct and it is now much harder to execute, because the buyer on the other side of the table has less working capital than they did last season and is being told no by their own lender.
This is the part most sector commentary misses. It reads 2026 as a funding story and prescribes revenue, without accounting for the fact that the money has to come out of a tighter budget than the one that existed when the plan was written. Any plan that accounts for one squeeze and not the other is solving the easier problem.
It does not make revenue the wrong goal. It makes urgency the thing you have to prove rather than assume, and it means a segment that converted in 2023 may not convert now for reasons that have nothing to do with your product.
Is a bridge round still a realistic plan?
For most pre-Series B ag and food tech companies, no.
A bridge assumes an investor will extend runway to reach a milestone that unlocks the next priced round. That depends on the next round existing. With deal activity down sharply and exits returning little capital to limited partners, most investors are triaging portfolios rather than extending them. If your 18-month plan still has a bridge in it, replace that line with something you control.
What are your actual options when you can't raise?
There are three, and they are not interchangeable.
Path 1. Reach repeatable revenue. Fund the business from customers.
Path 2. Replace equity with non-dilutive capital. Grants, customer-funded development, asset financing.
Path 3. Preserve runway. Shrink deliberately until the market reopens.
Which one leads depends on two variables: how close you are to a sale that repeats, and how many months of runway you have. Repeatable sale within reach and the runway to get there, take it. Technical, regulatory, or cost structure work still standing between you and a market, non-dilutive is the honest answer. Neither, preserve runway and start before the decision gets made for you.
Most companies run some version of all three. Only one can be the organizing priority, and running all three at full effort is how you do none of them well.
Only the first path changes your position. Non-dilutive capital and cost discipline buy months, and months alone do not make a company more valuable. If you choose either, decide up front what you will have accomplished by the time the money or the runway runs out. Reaching the end in the same position you started is the most common way this goes wrong.
That is not an argument for always choosing revenue. There are four situations where pushing for it is the wrong call, and they are worth checking honestly before committing a year to it.
You cannot legally sell yet. Biologicals and crop protection products require EPA registration. Novel food ingredients require a GRAS conclusion or FDA review. Animal products go through FDA's Center for Veterinary Medicine, and gene-edited traits through USDA APHIS. Those timelines run in years and commercial effort does not compress them. Until the gate clears, a commercial team builds pipeline you cannot invoice.
The window already closed. Ag purchasing clusters into a few weeks a year. If the ordering window for the coming season has passed, or your route to market runs through a retail program whose lineup was set months ago, there is no revenue available to you for another full cycle regardless of how good the offer is. That is a calendar problem, and no amount of selling fixes a calendar.
Your unit economics get worse with volume. If gross margin is negative at the volume you can actually finance, every additional sale burns cash faster. This is the failure mode behind several of the sector's largest collapses, and it is the one most often misdiagnosed as a go-to-market problem. More revenue is not the fix. Cost per unit is.
Technical risk is unresolved and the sales cycle is longer than your runway. A commercial push here buys you two discounted deals, a reference price you cannot repeat, and the same open technical question you started with.
In any of those four, the honest answer is Path 2 or Path 3, and building a commercial function is the expensive mistake. If a regulator, a cost structure, or an unfinished scientific question is what stands between you and a market, fund that instead. Part 2 covers how to pay for it without giving up equity.
Path 1: Can you reach repeatable revenue this year?
The goal is revenue you can repeat. Not any revenue, and not a signed contract.
One lighthouse deal closed by the founder at a steep discount funds very little and proves less. Repeatable means the same sale can happen again, to a different buyer, without a discount and without heroics. That is what pays the bills now and what makes you fundable later.
Agriculture makes this harder than the software version of the same advice, because there is roughly one buying window a year. A completed second purchase can sit eighteen to twenty-four months out, which is longer than many companies have. So the goal inside one season is not two closed sales. It is a first sale at a price you can repeat, into a segment specific enough to go find the next one, that the buyer themselves calls a success. Not a success by your metrics. A success by whatever number they already use to judge whether something worked on their operation. Your verdict on the first season does not travel. Theirs does, to their agronomist and to the operation next door. That is provable this year.
Three things decide whether that happens: who you go after, how the deal is structured, and whether the first sale is built to produce a second one.
Find the problem that is already costing money this season
Most teams segment by fit. Who the product works for, what operation size, what crop, what geography. That list is technically correct and commercially unreliable, because a buyer can match your profile exactly and still not buy. The problem is real, it is just not urgent enough to displace something else in this year's budget. That converted fine when money was cheap and both sides could afford a long nurture cycle.
It does not convert against the balance sheet described above. A buyer with less working capital than last season does not fund a real problem, they fund the one that is already costing them money this season.
So run every segment on your list through three questions before you spend another dollar against it.
What is this problem costing them this season, in their units? Dollars per acre, dollars per head, hours per week, percentage of crop lost. If you cannot say it in a number the buyer would recognize as their own, you are guessing at urgency.
Who signs, and what does your product displace? This differs by buyer and conflating the two types is expensive. Processors, co-ops, and corporates have real budget lines and sometimes innovation budgets. A row crop grower generally does not have a line waiting for you. They have a crop plan set in the fall with a trusted advisor and often financed, so you are not filling an empty slot, you are displacing a spend somebody already recommended. You need to know what you are taking the money from.
Can you name ten more operations like this one? If you cannot list them, you do not have a segment, you have a customer. Repeatability starts here, not at the second contract.
A segment that fails any one of the three gets no sales effort and no engineering time this year. Not never. Just not with this year's money. Write the list down, draw a line, and hold it, because the cost of not holding it is drift: a custom feature for a promising account, a trial in a different crop because someone asked, a distributor in a new geography who seemed motivated. Each is defensible on its own. Six months later you are running four go-to-market motions on one budget and none has enough behind it to close.
Make the deal terms fund the business
Price and payment timing are the same conversation, and both decide whether a signed contract actually helps you.
Discounting to win an early customer feels like momentum. What it does is set a reference price that follows you, because this industry is small and buyers talk. Your investor will model from it, and raising it later means re-justifying your value to people who already agreed to a different number. A discounted deal is also, by definition, not repeatable at full price.
The pressure is real. Another 42% of producers say input costs are actively limiting their financial position this year, and they will ask. But the answer is not a lower price, it is a defensible one. Buyers are not looking for cheap, they are looking for a number they can defend to whoever approves it. "Twelve percent yield improvement" loses to "pays back inside one season" almost every time, because only one survives the conversation you are not in the room for.
There is a second objection underneath the price one, and missing it costs deals. Growers do not evaluate your average return, they evaluate the downside. A season is a one-shot bet, and a product that underperforms does not cost them the purchase price, it costs them the crop. That is why an offer that reduces variance often beats one that raises the average, and why performance guarantees, staged commitments, and shared risk close deals that a better yield number will not.
Payment timing is the part most teams inherit rather than negotiate, and in agriculture that is expensive. Growers pay after harvest. Distributors want terms and often want you to carry inventory. You can book a strong year and run out of cash in month seven. Deposits, annual billing in advance, and who owns inventory are commercial terms, not finance details. Fall prepay is the most useful of them and the least understood: growers prepay for next season partly to pull the deduction into the current tax year, which is why the incentive works and why the window is the end of the calendar year rather than whenever you happen to ask. If you have to move on something to close, move on structure rather than price.
The second sale is won during the first one
Revenue from a customer who already bought is the cheapest revenue there is. No acquisition cost, no new proof burden, no procurement relationship to build. Early companies underweight it because logo count is what gets reported: fifteen customers reads as progress, while six customers who each bought more reads as a smaller number and is a considerably better business.
In agriculture you usually cannot collect it this season. With one buying window a year, the second purchase lands a full season after the first. So this is not a way to raise revenue in the current year. It is what decides whether next year's number exists at all, and nearly all of it is determined before the first sale closes. Three things have to be true at signing.
You and the buyer agree up front what success will look like, in their numbers. This is the one that costs teams the most. There is a difference between a customer who liked working with you and a customer who can tell you what your product did for their operation. The first is goodwill. The second is what they repeat to a neighbor and what justifies more acres. Teams arrive at the reorder conversation with the first and assume it counts as the second, because nobody agreed at the start what would be measured, in what unit, or who would record it. A grower who enjoyed the season will still not commit more acres without a figure they can set against their own cost per acre. If it was not captured while the crop was in the ground, it does not exist in the fall, and no amount of goodwill substitutes for it.
The trusted advisor is part of the first result. Adoption here spreads geographically and socially, so the second sale is frequently the neighbor rather than the same operation, and the person who decides whether that happens is usually the agronomist or retailer both growers rely on. If that advisor was not involved in the first season, they have nothing to carry into the next one.
The conversation opens before the season ends. Ordering decisions get made months ahead, often before the end of the calendar year. Waiting for full-season results and then raising expansion means the decision was already made without you. Most teams run this backward.
What if repeatable revenue isn't reachable this year?
Then you are choosing between the other two paths, and both are covered in full in the rest of this series.
Non-dilutive capital replaces equity without giving any up: federal and state grants, equipment and asset financing, and customer-funded development, which is the most underused of the three because teams treat it as a finance question when it is a commercial one. The catch is timing. Grant cycles run on quarters, not weeks, which makes this a decision you make while you still have runway. Part 2 covers what is actually available and how to sequence it.
Preserving runway is the option nobody wants to write about, which is why it gets executed badly. The useful question is not how much to cut but what has to survive intact, and when to act while you still have leverage. Part 3 covers how to do it without destroying the company you are trying to save.
There is also a fourth answer the sector rarely writes down, which is that some companies should sell or wind down deliberately while there is still something to sell. Part 3 says it plainly, because the founders who face that question at month eighteen do considerably better than the ones who face it at month twenty-four.
Is capital still available for ag and food tech?
Yes, and pretending otherwise is its own mistake. Anterra Capital closed a $100 million Fund III on the argument that demand for AI-driven innovation in food and agriculture is accelerating, calling this the sector's most attractive deployment moment in twelve years.
What changed is the bar. Capital is going to companies that can show contracted revenue, a named repeat buyer, gross margin at current volume, and a documented path from pilot to purchase order. Those are the same four things a company on the repeatable revenue path builds anyway.
One tension is worth naming rather than papering over. Venture underwrites growth rate, not durability, and a modest number attached to a real contract can be harder to raise against than a story with no number in it. Discipline can make you a better company and a narrower venture case at once. Anyone who tells you otherwise is selling something.
The answer is still not to avoid the number. A company with contracted revenue and a working cost structure has more than one way out of this market: a priced round, a strategic buyer, or not needing either for a while. A company with only a story has one, and it depends on a market PitchBook does not expect back before 2027.
Frequently asked questions
How much did agtech venture funding fall in 2026?
PitchBook recorded 263 agtech deals worth $2.4 billion in the first half of 2026, with 107 deals in Q2, the lowest quarterly deal count in its visible series. Against 875 deals in all of 2025, that is an annualized pace roughly 40% lower. Early counts revise upward as late deals are reported, so treat 40% as an upper bound on the decline rather than a settled figure.
When will agtech venture funding recover?
PitchBook expects 2026 to be the bottom of the cycle rather than the year of recovery, with a clearer rebound in 2027 once the exit market reopens and LP capital loosens. Any bump in the second half of 2026 is more likely to appear in total dollars than in deal count.
What should an ag or food tech startup do when it cannot raise?
There are three options: reach repeatable revenue, replace equity with non-dilutive capital, or preserve runway until the market reopens. Which one leads depends on how close the company is to a sale that repeats and how many months of runway it has. Only the first improves the company's position rather than extending it, but revenue is not always available. A company waiting on regulatory approval, locked out of the current season's buying window, or carrying negative gross margin at financeable volume should not lead with a commercial push.
Does growing without venture funding hurt your next round?
No. The proof points that make a company fundable in a down market, meaning contracted revenue, a repeat buyer, gross margin at current volume, and a documented pilot-to-purchase-order path, are the same ones revenue-funded growth produces.
Farm economy figures in this article are drawn from the USDA Economic Research Service farm income forecast and the Federal Reserve, current as of August 2026. USDA revises its forecast three times a year, so figures cited here reflect the forecast in effect at publication rather than final-year actuals.
If you are deciding which of these three paths is yours, that is a conversation worth having with someone who has run all three. 9 North Group embeds with ag and food tech teams as fractional operators to drive commercial outcomes. We don't just advise. We build. Schedule a strategy session.
